A head-to-head comparison of two commercial gene sequencing tests yielded differing results.
Rapid, robust, and affordable genetic testing for patients with ovarian cancer that allows a much larger portion of patients to benefit from personalized cancer management and their relatives to benefit from preventive strategies can be achieved.
Disparities in cancer risk management among BRCA carriers across a diverse sample of young black, Hispanic, and non-Hispanic white breast cancer survivors underscores that "the benefit from genetic testing comes from acting on the test results," not just the testing itself, a study presented at the ASCO 2016 Annual Meeting concluded.
Multiplex gene testing of diverse patients has found that patients who test positive advise relatives to test, "suggesting that participants understood the implications of test results," according to results of a planned interim analysis of a prospective trial presented at the ASCO 2016 Annual Meeting.
"In the absence of patient-matched germline data, large germline databases are required in analysis workflows to minimize false positive mutation calling and mitigate ethnic disparities," a study presented at the ASCO 2016 Annual Meeting concluded.
Results showed that telephone disclosure was not worse than in-person disclosure for general and state anxiety.
No Clinical Benefit to Expanding Gene Panel Beyond Ovarian and Breast Cancer Genes in High-risk WomenMay 20, 2016
Expanding a panel of tested genes beyond the known breast and ovarian cancer-specific genes in patients with breast and ovarian cancer did not confer any clinical benefit.
An analysis of test results can help women who won't benefit from additional treatment avoid potential side effects.
Among women age 40 years or younger, rates of genetic testing for BRCA1 and BRCA2 mutations have increased, according to a recent study.
Young patients with HER2+ breast cancer and no family history have low risk of carrying high risk genesDecember 29, 2015
A recent study examined genetic susceptibility in younger patients diagnosed with HER2+ breast cancer.
A stool DNA test for colorectal cancer was found to be an accurate noninvasive screening option for Alaska Native people, a population with one of the highest rates of colorectal cancer in the world, according to a recent study.
A widely available, inexpensive blood test can predict outcomes and guide treatment in pancreatic cancer; however, only 1 in 5 US patients with the disease have the blood test.
A new study has uncovered four new genetic variants associated with increased risk of testicular cancer. Testing for these and all 21 previously identified variants using genetic sequencing identified men at higher risk of testicular cancer.
Use of chemotherapy is inverse to disease risk in patients with breast cancer when genetic assay is usedSeptember 23, 2015
Use of the 21-gene recurrence test score was associated with lower chemotherapy use in high-risk patients and greater use of chemotherapy in low-risk patients compared with not using the test score among a large group of Medicare beneficiaries, according to a recent investigation.
Multigene testing of women negative for BRCA1 and BRCA2 uncovered other harmful genetic mutations.
New research indicates that many genetic alterations identified using tumor-only sequencing are not actually associated with the cancer, but instead reflect inherited germline mutations already present in the normal cells of the person.
Women with ovarian cancer should be tested for BRCA1 and BRCA2 gene mutations, regardless of their family history.
Near one quarter of patients with advanced lung cancer in Europe, Asia, and the United States are not receiving EGFR test results before being started on treatment, researchers found.
For many women with breast cancer, there is concern about the genetic risk of developing other cancers themselves or of a loved one developing cancer.
Most cancer patients want tumor profiling, but have mixed feelings about other genetic information the tests may revealApril 22, 2015
A majority of patients with cancer desire tumor profiling, even if the test would reveal risks for other genetic diseases.
Current practice of only focusing on tumor samples in genetic tests might adversely affect care, according to some researchers.
This fact sheet reviews genetic testing for cancer risk, including currently available genetic tests, recommendations for testing, positive and negative result definitions, and direct-to-consumer tests.
Although many patients with breast cancer are concerned about genetic risk for other cancer types, almost half don't have conversation with doctor about potential for future problems.
But researchers wonder if everyone is adept at accurately interpreting genetic test results.
Counseling from a health care professional trained in genetics before genetic testing takes place may improve the quality of health care.
A questionnaire can help counselors address psychosocial issues in genetic counseling for cancer.
Researchers have created a microchip device that can capture circulating tumor cells, in order to track ongoing genetic mutation within a tumor.
Health care professionals trained in genetics may improve quality of care and reduce unnecessary testingJuly 11, 2014
Counseling from a health care professional trained in genetics before genetic testing takes place may improve the quality of health care and help reduce unnecessary testing.
Barriers to obtaining gene expression profiling tests increased their perceived importance among patients with early breast cancer (estrogen-receptor positive [ER+], human epidermal growth-factor receptor 2 negative [HER2-], and node negative) who were deciding whether to have chemotherapy after surgery, according to a new study from Canada.
A simple, noninvasive blood test matched with state-of-the-art molecular imaging of individual cells could help oncologists understand their patients' chances of survival.
- Ruxolitinib May Improve Symptom Control in Patients With CLL
- 3-drug Regimen With Ricolinostat Active, Safe in Multiple Myeloma
- Lung Cancer Navigator App Aims to Help Patients Understand Disease
- Racial Disparities Persist in Myeloma Treatment Use
- Adding Bortezomib to Rd Improves PFS, OS in Newly Diagnosed Myeloma
- Optimal Timing of Influenza Vaccination in Patients Receiving Chemotherapy
- Racial Disparities Persist in Myeloma Treatment Use
- Hypnosis and Its Use in Cancer Treatment
- Longer Dosing Interval of Zoledronic Acid May Be Acceptable for Bone Metastases
- Melanoma Incidence Still on the Rise in Parts of the United States
- Frailty Classifications Associated With Prognosis Among Older Patients
- Beach Umbrella Not Enough for Protection from UV Rays
- Comprehensive Report Looks at Benefits and Harms of Medical Cannabis
- ASCO: Moderate Activity Linked to Longer Survival in Advanced CRC
- MABp1 Improves Symptoms vs Placebo in Colorectal Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|